Get started
Author

Yoshiaki Shindo

Observed names: Shindo, Yoshiaki, Y. Shindo, YOSHIAKI SHINDO, Yoshiaki SHINDO
ORCID: 0000-0002-4931-2545
Observed ORCID: 0000-0002-4931-2545
OpenAlex ID: A5102810917
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
2022 · Yasuyuki Kawamoto, Satoshi Yuki, et al. · The Oncologist · 23
PDF
Phase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial
2018 · H. Osawa, E. Shinozaki, et al. · Annals of Oncology · 19
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
2016 · Masato Nakamura, Toru Aoyama, et al. · Cancer Chemotherapy and Pharmacology · 15
PDF
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer
2022 · Ken Ito, Satoshi Yuki, et al. · Supportive Care in Cancer · 13
PDF
Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial.
2019 · Yoshihito Ohhara, Eiji Shinozaki, et al. · Journal of Clinical Oncology · 13
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study
2025 · Toru Aoyama, Akira Ooki, et al. · International Journal of Clinical Oncology · 9
PDF
Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).
2021 · Yasuyuki Kawamoto, Satoshi Yuki, et al. · Journal of Clinical Oncology · 7
Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study
2018 · Shunsuke Kato, Hiroo Imai, et al. · The Tohoku Journal of Experimental Medicine · 7
PDF
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study
2023 · Ryohei Kawabata, Keisho Chin, et al. · Gastric Cancer · 6
PDF
Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study
2022 · Ryo Inada, Takeshi Nagasaka, et al. · European Journal of Cancer · 5
PDF
Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203)
2021 · Masanobu Takahashi, Yasuhiro Sakamoto, et al. · The Tohoku Journal of Experimental Medicine · 5
PDF
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
2019 · Hiroaki Tanioka, Takeshi Nagasaka, et al. · BMC Cancer · 5
PDF
Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201
2023 · Shin Takahashi, Kota Ouchi, et al. · Journal of Gastrointestinal Oncology · 4
PDF
Randomized controlled trial of the significance of combined use with Ninjin’yoeito in CapeOX + Bmab therapy for patients with unresectable advanced/recurrent colorectal cancer: A protocol for study on efficacy, safety, and interaction (NYX study)
2022 · Yoshiharu Motoo, Katsunori Shinozaki, et al. · Medicine Case Reports and Study Protocols · 4
Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel–Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan
2026 · Takeshi Nagasaka, Yoshiyasu Kono, et al. · Cancers · 2
A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903)
2026 · Yasuyuki Kawamoto, Kentaro Sawada, et al. · Gastric Cancer · 2
PDF
Results of a phase 2 trial of ramucirumab plus docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
2025 · Kentaro Sawada, Yasuyuki Kawamoto, et al. · Journal of Clinical Oncology · 2
PDF
Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies
2022 · Hiroshi Nakatsumi, Yoshito Komatsu, et al. · Frontiers in Oncology · 2
PDF
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer
2022 · Shintaro Nakano, Yasuyuki Kawamoto, et al. · BMJ Open · 2
PDF
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial
2022 · KEISHO CHIN, DAISUKE TAKAHARI, et al. · Anticancer Research · 2
PDF
Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: The subgroup-analysis of DEEPER trial (JACCRO CC-13).
2022 · Hironaga Satake, Akihito Tsuji, et al. · Journal of Clinical Oncology · 2
Changes in plasma cfDNA ERBB2 copy number reflect prognosis in HER2-positive gastric cancer: a correlative analysis of the KSCC-TROX A2 study
2026 · Yuki Shin, Akitaka Makiyama, et al. · International Journal of Clinical Oncology · 1
T-CORE2401 trial: A randomized phase II trial of mFOLFOX6 plus cetuximab versus mFOLFOX6 plus bevacizumab as first-line treatment for right-sided, RAS / BRAF wild-type, low-methylated metastatic colon cancer.
2026 · Kota Ouchi, Eiji Shinozaki, et al. · Journal of Clinical Oncology · 1
PDF
35P Clinical outcomes of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab by metastasis status in RAS/BRAF wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13)
2025 · Y. Sunakawa, M. Shiozawa, et al. · Annals of Oncology · 1
PDF
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study
2024 · Yoshiyuki Yamamoto, Hiroki Yukami, et al. · International Journal of Clinical Oncology · 1
Works count: 67
Citation count: 163
H-index: 7
I10-index: 5
Year
Topic
Type